COT Cotinga Pharmaceuticals Inc

Critical Outcome Technologies Inc. ("COTI" or the "Company") (TSX
VENTURE:COT)(OTCQB:COTQF), the bioinformatics and accelerated drug discovery
company, announced today that Dr. Wayne Danter, President & CEO, will introduce
"Project ROSALIND" in a podium presentation on June 25, 2014, at the annual BIO
International Convention in San Diego California. The Company will use the
hashtag #ROSALIND on Twitter for sharing more information with those not able to
attend the presentation in person. 


ROSALIND is a programmable computer simulation of cancer cell signaling,
designed to realize the therapeutic potential of the important information
derived from increasingly accessible cancer gene mutation profiles. The
underlying principle behind ROSALIND is that cancers are diseases of cell
signaling and any hope of sustained remission is dependent on therapies that
restore normal cell signaling to regulate cell division and apoptosis. 


"The goal of ROSALIND is to provide better personalized treatment options based
on the genetic profile of the patient's cancer," said Dr. Wayne Danter. "While
access to high-quality cancer gene mutation profiling continues to evolve, it
has not been possible to use that information for truly personalized cancer
therapy prior to ROSALIND. Personalized cancer therapy has been a big data
problem. For example, the number of unique single, double, and triple drug
combinations from just 150 cancer drugs would be in excess of 540,000. This is
simply too many potential therapies for any physician or group of physicians to
evaluate. ROSALIND addresses this big data problem."  


"We are quite pleased with the results of our ongoing validation of this
game-changing technology and are talking with a number of potential partners
about commercial validation opportunities," added Dr. Danter.


About Critical Outcome Technologies Inc. 

COTI is a leading-edge bioinformatics company specializing in accelerating the
discovery and development of small molecules - dramatically reducing the time
and cost to bring new drugs to market. COTI's proprietary artificial
intelligence system, CHEMSAS(R), utilizes a series of predictive computer models
to identify compounds with a high probability of being successfully developed
from disease specific drug discovery through chemical optimization and
preclinical testing. These compounds are targeted for a variety of diseases,
particularly those for which current treatments are either lacking or
ineffective. 


For more information, visit www.criticaloutcome.com.

Follow @CriticalOutcome on Twitter at http://twitter.com/CriticalOutcome 

Notice to Readers 

Information contained in this press release may contain certain statements,
which constitute "forward-looking statements" within the meaning of the
Securities Act (Ontario) and applicable securities laws. For example, the
statement, "... of this game-changing technology and are talking with a number
of potential partners about commercial validation opportunities" is a
forward-looking statement. Forward-looking statements by their nature are not
guarantees of future performance and are based upon management's current
expectations, estimates, projections and assumptions. COTI operates in a highly
competitive environment that involves significant risks and uncertainties, which
could cause actual results to differ materially from those anticipated in these
forward-looking statements. Management of COTI considers the assumptions on
which these forward-looking statements are based to be reasonable, but as a
result of the many risk factors, cautions the reader that actual results could
differ materially from those expressed or implied in these forward-looking
statements. Information in this press release should be considered accurate only
as of the date of the release and may be superseded by more recent information
disclosed in later press releases, filings with the securities regulatory
authorities or otherwise.


Neither TSX Venture Exchange nor its Regulation Services Provider (as that term
is defined in the policies of the TSX Venture Exchange) accepts responsibility
for the adequacy or accuracy of this release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Critical Outcome Technologies Inc.
Dr. Wayne Danter
President & CEO
519-858-5157
wdanter@criticaloutcome.com
www.criticaloutcome.com


Heisler Communications
Trevor Heisler
Investor Relations
416-500-8061
trevor@heislercommunications.com

Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From Nov 2024 to Dec 2024

Cotinga Pharmaceuticals (TSXV:COT)
Historical Stock Chart
From Dec 2023 to Dec 2024